Failure of thromboxane synthetase inhibition to improve exercise tolerance in patients with stable angina pectoris.
We report the results of a double-blind study of dazoxiben in which treatment was continued for 3 weeks in patients with angiographically proven coronary artery disease who were receiving no other antiplatelet drugs.